Premium
MicroRNAs: Small molecules with a large impact on pre‐eclampsia
Author(s) -
Hemmatzadeh Maryam,
Shomali Navid,
Yousefzadeh Yousef,
Mohammadi Hamed,
Ghasemzadeh Aliyeh,
Yousefi Mehdi
Publication year - 2020
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.29286
Subject(s) - microrna , eclampsia , pregnancy , pathogenesis , disease , angiogenesis , bioinformatics , placenta , biology , medicine , fetus , immunology , cancer research , genetics , pathology , gene
As critical mediators in biological processes, microRNAs (miRNAs) which are small and endogenous noncoding RNAs have been associated with disease progression, cell proliferation, and development. Pre‐eclampsia (PE), a pregnancy‐related disorder with no early markers or symptoms is recognized as the main reason for fetal and maternal mortality and morbidity in the initial steps or even during pregnancy, worldwide. Clinical symptoms usually appear in the third trimester of the pregnancy. Although numerous research have unraveled several aspects of placenta development abnormalities associated with abnormal trophoblastic invasion and angiogenesis modification, many questions about the PE pathogenesis remains unanswered. A large number of studies have shown the important role of miRNAs as potential biomarkers in the PE prognosis and diagnosis. Here, the latest investigations about the PE and placental miRNAs expression, as well as, the crucial role of miRNA molecules including miR‐210 and miR‐155 which are deregulated in patients with PE, will be argued.